Fresenius Medical Care AG & Co. (ADR) (NYSE:FMS) had its Neutral rating reiterated by Royal Bank of Canada

ME Staff
-
0

Analyst Ratings For Fresenius Medical Care AG & Co. (ADR) (NYSE:FMS)

Today, Royal Bank of Canada reiterated its Neutral rating on Fresenius Medical Care AG & Co. (ADR) (NYSE:FMS).

There are 5 Buy Ratings, 4 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.

The current consensus rating on Fresenius Medical Care AG & Co. (ADR) (NYSE:FMS) is Buy with a consensus target price of $53.00 per share, a potential 8.23% upside.

Some recent analyst ratings include

  • 7/31/2018-Royal Bank of Canada Reiterated Rating of Neutral.
  • 7/9/2018-Bank of America initiated coverage with a Buy rating.
  • 7/5/2018-Credit Suisse Group was Downgraded by analysts at Credit Suisse Group from a “Outperform ” rating to a ” Neutral” rating. They now have a N/A price target on the stock.
  • 4/24/2018-Deutsche Bank Upgrade from a “Hold ” rating to a ” Buy” rating.
  • 4/23/2018-DZ Bank Reiterated Rating of Buy.
  • 1/4/2018-UBS Group Upgrade from a “Sell ” rating to a ” Neutral” rating.
  • 1/2/2018-Nord/LB Reiterated Rating of Buy.


    About Fresenius Medical Care AG & Co. (ADR) (NYSE:FMS)
    Fresenius Medical Care AG & Co. KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the U.S. for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company also develops, manufactures, and distributes dialysis products, including hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and water treatment systems for the treatment of ESRD; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, hospitalist and intensivist, medical cost management, ambulatory surgery center, health plan, urgent care, physician nephrology and cardiology, and ambulant treatment services. In addition, it develops, acquires, and in-licenses renal pharmaceuticals; and offers non-dialysis products, including acute cardiopulmonary and apheresis products. The company sells its products to clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. As of December 31, 2017, it operated 3,752 outpatient dialysis clinics in approximately 50 countries. The company has operations in Germany, the United States, and internationally. Fresenius Medical Care AG & Co. KGaA was founded in 1996 and is headquartered in Bad Homburg, Germany.

    Recent Trading Activity for Fresenius Medical Care AG & Co. (ADR) (NYSE:FMS)
    Shares of Fresenius Medical Care AG & Co. (ADR) closed the previous trading session at 48.88 −0.97 1.95% with 49.01 shares trading hands.